Navigation Links
U of U researchers to use patient's own stem cells to treat heart failure
Date:11/17/2008

SALT LAKE CITY Nov. 17, 2008 Researchers at the University of Utah are enrolling people in a new clinical trial that uses a patient's own stem cells to treat ischemic and non-ischemic heart failure.

The one-year Cardiac Repair Cell Treatment of Patients with Dilated Cardiomyopathy (IMPACT-DCM) study will look at the safety of injecting Cardiac Repair Cells (CRC) and their ability to improve heart function.

Patients enrolled in IMPACT-DCM will have their own bone marrow cells drawn (about 3 tablespoons worth), which will then be grown in a culture to expand the number of cells that will help the heart muscle and improve blood flow. Two weeks later, the patient's stem cells will be injected directly into the left ventricle of the heart during a minimally invasive surgery developed by Amit N. Patel, M.D., national principal investigator for the IMPACT-DCM trial and director of cardiovascular regenerative medicine at the University of Utah School of Medicine.

"Heart failure affects about 5 million Americans, with more than half a million new cases diagnosed each year. A subset of these patients has dilated cardiomyopathy (DCM), a condition that leaves the heart weakened, enlarged and unable to pump blood efficiently. For most of these patients, the only option has been a heart transplant," said David A. Bull, M.D., professor and division chief of Cardiothoracic Surgery in the U's medical school and site principal investigator for the trial.

"This is the first trial of its kind in the United States, providing patients who have limited to no other options with a viable treatment," said Patel, professor of surgery. "By using a patient's own cells, we eliminate the concern of rejection and the need for potentially harmful immunosuppressive drugs. We hope these cells will help with new blood vessels and support the heart muscle in order to improve the heart's function, thereby greatly improving the patient's quality of life."

Patients who have been diagnosed with congestive heart failure (NYHA Class 3 or 4) and are between the ages of 18 and 86 may be eligible to participate in the trial. The University of Utah is one of five nationwide sites conducting the IMPACT-DCM study, sponsored by Aastrom Biosciences, Inc., a company specializing in autologous cell products. IMPACT-DCM is a randomized, controlled, Phase II study that will enroll 40 patients nationwide: 20 patients with ischemic DCM and 20 patients with nonischemic DCM.


'/>"/>

Contact: Chantelle Turner
chantelle.turner@hsc.utah.edu
801-581-7387
University of Utah Health Sciences
Source:Eurekalert

Related medicine news :

1. Researchers identify toehold for HIVs assault on brain
2. Researchers Tackle CLL, Diabetes and Trauma-Hemorrhage
3. Researchers Use New Method to Control Bleeding in Hemophilia
4. Stem cells with potential to regenerate injured liver tissue identified by Penn researchers
5. Protein can nurture or devastate brain cells, depending on its friends, researchers find
6. Researchers find stem cells from monkey teeth can stimulate growth and generation of brain cells
7. Battling Bacteria in the Blood: U-M Researchers Tackle Deadly Infections
8. Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
9. USC researchers identify key mechanism that regulates the development of stem cells into neurons
10. Cornell researchers study showing evidence of a major environmental trigger for autism
11. Maastricht University researchers produce neural fingerprint of speech recognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2016)... Cary, North Carolina (PRWEB) , ... May 29, 2016 , ... ... requested. Now, via Amazon.com, their new KlipPro KP-240L clipper is available to the public. ... jaw which is substantially wider than the average clipper. , Everything about this ...
(Date:5/28/2016)... Hartford, CT (PRWEB) , ... May 28, 2016 , ... After a year and a ... report it was an extraordinary event. The Multiple Pathways of Recovery Conference was held ... from across the country and the United Kingdom came together to explore the many pathways ...
(Date:5/27/2016)... ... , ... W.S. Badger Co. Inc ., the maker of certified organic ... one of the best small businesses for new dads by Fatherly, the digital lifestyle ... providing progressive benefits to new parents on the organization’s 2016 Best Places to ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... to help educate the many who are unaware of the plight of aphasia. ... will run within the “Stroke Awareness” campaign. , The link between stroke and ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... in the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation ... providing proof of successfully certified products, services and staff. , Validation Center is ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016   ... primären Endpunkte und demonstriert Ebenbürtigkeit bei der ... ‚ausgezeichneter plus guter , Reinigung ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... Daten von der MORA-Studie der Phase III für ...
(Date:5/24/2016)... 2016  NxStage Medical, Inc. (Nasdaq: NXTM ... renal care, today announced that Jeffrey H. Burbank ... following schedule of investor conferences. Where applicable, a webcast ... http://ir.nxstage.com/ .   ... NY           Friday, June 10, 2016 1:30 p.m. ET ...
(Date:5/24/2016)... 24, 2016 Los innovadores ... del mundo, introduce catéteres para la intervención de ... una compañía global especializada en el suministro de ... su cartera incluyendo productos para tratar la enfermedad ... PTA son los dispositivos de primera entrada de ...
Breaking Medicine Technology: